A Phase 1 Multi-Centre, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics and Safety of Pomalidomide When Given in Combination With Low Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma and Impaired Renal Function
The purpose of this study is to determine the pharmacokinetics (PK) and safety for the
combination of pomalidomide (POM) + low-dose dexamethasone (LD-DEX) in subjects with
relapsed or refractory Multiple Myeloma (RRMM) and impaired renal function.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society